Thilo Schroeder is a partner at Nextech Invest in Zurich, Switzerland, a venture capital firm with a focus on oncology companies.
One prominent venture capitalist in the biotech sector had the following to say about him: “Oncology specialist, young guy, trying to build a fund and make a name for himself. Hard to do any which way, even harder from Europe. Traditional investor mode, but smart, good guy, and has made excellent picks.”
Dr. Schroeder is currently a member of the board of directors for Revolution Medicines, IDEAYA Bioscience and ImaginAb, a board observer of Peloton Therapeutics and a previous board member/observer of Blueprint Medicines, SiROP Global and Tracon Pharmaceuticals.
Prior to joining Nextech Invest, Dr. Schroeder worked in research on the development of Designed Ankyrin Repeat Proteins (DARPins) as specific protein inhibitors. He also operating experience in molecular biology as an intern at Germany-based Micromet (now Amgen) and during his studies at the University of Sydney.
He has a bachelor’s from the Technical University of Darmstadt in Germany, a master’s in biotechnology from the Ecole de Supérieure de Biotechnologie de Strasbourg in France, and a PhD in biochemistry from the University of Zurich in Switzerland.Tags: biochemistry, biotechnology, cancer, oncology, STEM, VC